A-Level Medical Physics: Nuclear Medicine & Radiotracers

Transient equilibrium occurs when a parent nuclide has a half-life slightly longer than its daughter. Using molybdenum-99 (half-life 66 hours) decaying to technetium-99m (half-life 6 hours) as an example, the daughter's activity initially grows and eventually exceeds the parent's activity. At t=0, with no technetium present, after 6 hours the technetium activity reaches approximately 0.482 GBq from a 1 GBq parent source. The key insight is that transient equilibrium happens because the daughter contains more atoms per unit activity than the parent (since λ₂ > λ₁ implies fewer atoms for the same activity).

Technetium-99m generators demonstrate practical applications of transient equilibrium in nuclear medicine. Molybdenum-99 (half-life 66 hours) decays to Technetium-99m (half-life 6 hours). Using the maximum time formula, Technetium-99m reaches maximum activity at approximately 32.8 hours. Hospitals receive Mo-99 columns weekly; Technetium-99m is eluted daily for diagnostic imaging. Despite transient equilibrium predicting daughter activity should exceed parent, Technetium-99m's gamma ray abundance factor (only 87% of decays emit diagnostic gamma rays) causes its measured gamma activity to be less than parent activity, explaining why the characteristic transient behavior isn't observed in practice.

Technetium-99m is produced from molybdenum-99 through a generator system exploiting their favorable half-life ratio (66 hours for Mo-99, 6 hours for Tc-99m), creating transient equilibrium reaching peak Tc-99m concentration after ~24 hours. The generator uses alumina absorbed with Mo-99; Tc-99m becomes water-soluble and is eluted with sterile saline. Modern practice increasingly uses unit-dose delivery systems where Tc-99m is delivered pre-prepared to hospitals based on scheduled study times. Technetium chemistry allows labeling with various compounds for diverse applications including bone scanning, cardiac imaging, and renal studies, making it the most versatile radiopharmaceutical in nuclear medicine.

The Technetium-99m generator is a critical medical device that produces Tc-99m for nuclear medicine imaging. It contains Mo-99 (half-life = 66 hours) which decays to produce Tc-99m (half-life = 6 hours). The generator works by fixing Mo-99 in a container while allowing Tc-99m to accumulate. When saline solution is passed through, Tc-99m is eluted (washed out) while Mo-99 remains. After elution, Mo-99 continues producing Tc-99m, enabling repeated elutions. The Tc-99m activity reaches maximum approximately 14 hours after elution. This system operates under transient equilibrium conditions, where the parent's half-life is longer than the daughter's but not extremely long, allowing the daughter's activity to eventually exceed the parent's at equilibrium.

When parent and daughter nuclei decay together, complex equilibrium patterns emerge. If parent half-life exceeds daughter's, equilibrium is reached after approximately four daughter half-lives. In transient equilibrium (parent slightly longer), daughter activity initially rises then decays with parent's half-life. In secular equilibrium (parent much longer), daughter activity approaches parent's activity. The daughter effectively behaves as if it has the parent's half-life once equilibrium is established. For example, Molybdenum-99 (66-hour half-life) decays to Technetium-99m (6-hour half-life), demonstrating transient equilibrium.

Single Photon Emission Computed Tomography (SPECT) reconstructs 3D radiotracer distributions using filtered back projection or iterative algorithms. The gamma camera rotates 180-360 degrees acquiring projections at multiple angles (64-128 views). Iterative reconstruction enables better noise handling, attenuation correction, and scatter correction. Multi-head cameras improve acquisition speed. SPECT provides better contrast resolution than planar imaging by eliminating superposition effects. Positron Emission Tomography (PET) detects pairs of 511 keV annihilation photons traveling in opposite directions, eliminating the need for physical collimation. Early PET used collimators to reduce random coincidences; modern systems use timing electronics. PET/CT and SPECT/CT combinations overlay functional nuclear images onto anatomical CT, enabling precise localization of metabolic or perfusion abnormalities. CT data also provides attenuation maps for correction of gamma ray attenuation during PET imaging.

SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) are nuclear medicine imaging techniques that use radioisotopes to visualize physiological processes in the body; SPECT detects gamma photons emitted directly from radioisotopes using rotating gamma cameras and reconstructs images through back-projection with filtering, while PET detects coincident photon pairs from positron annihilation events, providing superior spatial resolution without reconstruction; these techniques offer functional and molecular imaging capabilities that complement anatomical imaging methods like CT and MRI, with applications in cardiac, cerebral, pulmonary, and skeletal imaging for detecting tumors, metabolic disorders, and other pathologies.

PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) are advanced nuclear medicine imaging techniques. PET uses radiotracers that emit positrons, which annihilate with electrons to produce gamma rays detected by the scanner. SPECT uses gamma-emitting radiotracers detected by rotating cameras. These techniques measure metabolic activity, particularly glucose consumption in cancer cells. PET is essential for cancer staging, detecting micrometastases invisible on CT/MRI, and monitoring treatment response by quantifying metabolic changes. The technique can distinguish between remission (lesions disappear) and cure (no hidden micrometastases), with follow-up scans at 6-month intervals.

PET and SPECT imaging are molecular imaging techniques based on the tracer principle, where radiopharmaceuticals containing radioisotopes are administered to visualize biological processes; PET uses positron-emitting radioisotopes (cyclotron-produced, short half-lives) that undergo annihilation producing two 511 keV gamma rays detected via coincidence counting with electronic collimation, while SPECT uses single-photon emitting radioisotopes (reactor-generator or cyclotron-produced, longer half-lives) requiring physical collimation; both modalities acquire line integrals of tracer distribution along lines of response, which are reconstructed into tomographic images using either filtered back projection (with ramp filtering) or iterative methods like MLEM accelerated by ordered subsets (OSEM), with PET offering better quantitative capabilities when proper corrections for attenuation and scatter are applied.

SPECT (Single Photon Emission Computed Tomography) overcomes gamma camera limitations by rotating around the patient to capture multi-angle projections, which are reconstructed into three-dimensional images showing coronal, sagittal, and transverse slices. PET (Positron Emission Tomography) achieves even greater precision through coincidence detection of annihilation photons, enabling molecular-level imaging of physiological processes including metabolism and receptor binding. These technologies represent the cutting edge of nuclear medicine, providing unprecedented detail for diagnosing complex conditions and guiding treatment decisions.

Radiation dose is measured as exposure (ionization in air), absorbed dose (energy per mass in Gray), and effective dose (biological risk in Sievert). Different radiation types have different biological effectiveness: X-rays/gamma rays (WR=1), alpha particles (WR=20). Tissue weighting factors account for varying organ sensitivities. Effective dose sums weighted doses across all tissues. The ALARA principle (As Low As Reasonably Achievable) requires minimizing radiation dose while maintaining diagnostic quality. Three pillars guide protection: justification (benefits outweigh harms), optimization (best method for diagnostic goals), and ALARA (lowest reasonable dose). Clinical justification requires evaluating whether imaging provides necessary diagnostic information. Anatomical knowledge prevents inappropriate requests (e.g., frontal sinus X-ray in children without developed sinuses).

This section presents effective dose as a conceptual framework for comparing biological risks between different diagnostic exams, distinguishing it clearly from individual patient dose estimation. Effective dose represents the whole-body uniform radiation dose reflecting the same biological risk as the actual non-uniform radiation delivered to a fraction of the patient's body. It is calculated by multiplying DLP by a conversion factor (K factor) that depends on patient size, body region, and assumed CTDI phantom. However, the section critically analyzes limitations: effective dose is NOT defined for individual patients—it was originally designed for radiation protection of occupationally exposed workers. K factors were developed assuming DLP represented actual patient dose, so using SSD instead of CTDIvol would require new K factors. The section concludes that effective dose should only be used to compare biological effects between different types of diagnostic exams in populations, not for individual patient dose tracking or documentation.

Radiation dosimetry involves measuring radiation effects through physical and biological measurements: absorbed dose (energy/mass in grays), exposure (charge per kilogram), and kerma (energy transferred to electrons); biological measurements include equivalent dose (absorbed dose × radiation weighting factor, e.g., alpha=20, photons=1) and effective dose (equivalent dose × tissue weighting factor, summing to 1 for whole body), enabling comparison of radiation risks across different exposure scenarios.

Dosimetric quantities are calculated as follows: absorbed dose (Gy) multiplied by radiation quality factor (Qr) gives equivalent dose (Sv). Equivalent dose to an organ multiplied by tissue weighting factors gives effective dose (Sv), the most important parameter in radioprotection. The ICRP 2008 report showed radiography and mammography doses decreased significantly over time, while CT doses increased substantially. The NCRP Report 184 (2016) revealed that while radiography and fluoroscopy constitute 74% of X-ray studies, they contribute only 10% to population effective dose, while CT contributes 63%. ICRP Report 74 decided that for medical imaging risk evaluation, detailed organ dose knowledge is required instead of effective dose. Converting absorbed dose to effective dose introduces approximately 40% error, with total uncertainty reaching 500% when combined with cancer study uncertainties.

Radiation dose is measured using dosimeters (dozimetre), with monthly evaluations for radiation workers. If dose exceeds limits, workers receive a 15-day 'shua leave' (şua izni) to eliminate accumulated radiation. This leave is paid and doesn't count against annual leave. Dose limits vary: workers can receive 50 mSv annually (20 mSv over 5 years), while the general public is limited to 5 mSv annually. Lens of eye limit is 150 mSv, skin is 500 mSv. For workers under 18, limits are 6 mSv annually.

Iodine-123 is harmless to thyroid cells and is used for visualizing the thyroid, serving as a good alternative to technetium. Iodine-131 destroys thyroid tissue and is used to treat thyroid cancer and Graves disease. Iodine-131 produces a higher radiation dose than Iodine-123. Both tracers serve different purposes in nuclear medicine.

Nuclear medicine is a diagnostic imaging specialty that evaluates metabolism and physiology of organs or systems, divided into diagnostic imaging (including static images like planar and SPECT using Technetium-99m, dynamic imaging, and PET using Fluorine-18) and therapeutic applications using radioisotopes such as Iodine-131 for thyroid cancer, Lutetium-177 for neuroendocrine tumors, Radium-223 for prostate cancer bone metastases, and Samarium-153 for bone metastases.

Nuclear medicine is a medical field that uses radioactive tracers (radiopharmaceuticals) for both diagnosis and treatment; diagnostic applications like FDG-PET scans track metabolic processes to detect cancer and neurological diseases, while therapeutic applications use targeted radiation (such as Iodine-131 for thyroid cancer or Lutetium-177 for prostate cancer) to destroy diseased cells, with safety ensured through minimal radiation doses and short half-life isotopes.

Nuclear medicine differs fundamentally from radiology by utilizing radiation emitted from within atomic nuclei (gamma rays, alpha/beta particles) rather than external sources. Diagnostic applications include gamma-emitting radioisotopes for imaging (DTPA, DMSA, MIBG, cardiac stress, bone scans) and PET/CT for malignancy staging. Therapeutic applications use high-cell-killing radioactive materials: radioactive iodine for thyroid cancer, PSMA therapy for prostate cancer, Lu-177 DOTATATE for neuroendocrine tumors, Samarium-153 for bone pain, and Yttrium-90 for liver cancer. Theranostics integrates diagnostic and therapeutic approaches using identical molecular targeting agents.

Nuclear medicine uses radioactive tracers (radioactive materials attached to chemical compounds) to diagnose and treat diseases. A small amount of radioactive material is injected into the patient, and a gamma camera detects the radiation to create images of internal organs. Radiation therapy uses controlled radiation to destroy cancer cells, with gamma rays directed at tumor cells to damage their DNA. Radioactive iodine-131 is specifically used to treat thyroid disorders and thyroid cancer.